SEC Form 4/A · accession 0001552781-16-002003
MACROGENICS INC · MGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Jon Marc Wigginton
Officer — Sr VP, Clinical Dev. & CMO
Period of report
Oct 3, 2016
Accepted (ET)
Oct 19, 2016 · 5:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001125345
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 3, 2016 | M | 10,000 | $4.70 | A | 10,000 | D | |
| Common StockF1,F2 | Oct 3, 2016 | S | 10,000 | $29.34 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $4.70 | Oct 3, 2016 | M | 10,000 | D | Jan 18, 2014 | Jul 18, 2023 | Common Stock | 10,000 | 25,254 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016.
- F2This transaction was executed in multiple trades at prices ranging from $28.755 to $29.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Due to a clerical error, the reporting person is filing this amendment to the Form 4 originally filed on October 5, 2016 to correct the number of derivative securities beneficially owned following the reported transaction from 15,254 to 25,254.